NBTXR3: Ph II/III Act.In.Sarc ongoing

An IDMC recommended continuation of the open-label, international Phase II/III Act.In.Sarc trial of a single intratumoral injection of NBTXR3 followed by radiotherapy and surgery based on safety and efficacy data from 104 patients. Act.In.Sarc is comparing NBTXR3 vs. radiotherapy followed by surgery in 156 patients...